Skip to Content

Nascent Biotech Inc - Stock Quote NBIO

Rating as of

Morningstar's Nascent Biotech Inc Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics - NBIO

Nascent Biotech Inc's Company Profile

Business Description

Nascent Biotech Inc is a United States-based clinical stage biopharmaceutical company. It is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. It is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. They are also exploring the use of Pritumumab against other viruses.

Contact
623 17th Street, Suite 4
Vero Beach, FL, 32960
T +1 612 961-5656
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Mar 31, 2023
Stock Type Slow Growth
Employees